First-Line Pembrolizumab Monotherapy for Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Study from Vietnam.
Simple Summary: Lung cancer is one of the most common malignancies and the leading cause of cancer-related death in Vietnam. Pembrolizumab monotherapy is approved as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK mutations and with PD-L1 expr...
| Published in: | Current Oncology Vol. 33; no. 4; pp. 215 - 231 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Published: |
MDPI
Apr2026
|
| Online Access: | View this record in EBSCOhost |